TFV + LNG Vaginal Ring

Alternative Name: Tenofovir (TFV) and levonorgestrel (LNG) ring

Description: An ARV-based microbicide, tenofovir, and a progestin-only contraceptive, levonorgestrel, in a two-segment polyurethane vaginal ring.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Vaginal Ring

Duration Type: Short-acting

Duration: 90 days

Dose: 10-20 ug LNG (per day), 10 mg TFV (per day)

Active Pharmaceutical Ingredient (API):
  • levonorgestrel
  • tenofovir

Inactive material: polyurethane

Multipurpose Preventive Technology (MPT): Yes

Status Details

Developer: CONRAD

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase I

Active Development: Yes

Status Details:
  • Phase 1 safety and PK/PD trial that began in late 2014 was completed.

Additional Information

References:
  • Clark JT, et al. (2014) Engineering a Segmented Dual-Reservoir Polyurethane Intravaginal Ring for Simultaneous Prevention of HIV Transmission and Unwanted Pregnancy. PLoS ONE. 9(3): e88509.

  • Thurman AR, et al. (2018) Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. PLoS One. 13(6); e0199778.

  • Press Release: www.conrad.org/news-pressreleases-93.html

  • CONRAD website: www.conrad.org/prevention-trials.html

  • Clinicaltrials.gov Identified NCT02235662

Vertical Tabs

Print